197 related articles for article (PubMed ID: 22975552)
1. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
Intern Med; 2012; 51(17):2375-8. PubMed ID: 22975552
[TBL] [Abstract][Full Text] [Related]
2. A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report.
Nomoto H; Miyoshi H; Nakamura A; Nagai S; Kitao N; Shimizu C; Atsumi T
Medicine (Baltimore); 2017 Sep; 96(39):e8147. PubMed ID: 28953654
[TBL] [Abstract][Full Text] [Related]
3. Iatrogenic osteomalacia: report of two cases.
Yamamoto S; Okada Y; Mori H; Kurozumi A; Torimoto K; Arao T; Tanaka Y
J UOEH; 2013 Mar; 35(1):25-31. PubMed ID: 23475021
[TBL] [Abstract][Full Text] [Related]
4. [Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
Wada Y; Kinoshita Y; Taguchi M; Fukumoto S; Fujita T
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):3031-3. PubMed ID: 22175146
[No Abstract] [Full Text] [Related]
5. Uncommon adverse effect of a common medication.
Moore KL; Kildahl-Andersen O; Kildahl-Andersen R; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2013 Jan; 133(2):165. PubMed ID: 23344600
[No Abstract] [Full Text] [Related]
6. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
[No Abstract] [Full Text] [Related]
7. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.
Sato K; Shiraki M
Endocr J; 1998 Aug; 45(4):431-9. PubMed ID: 9881891
[TBL] [Abstract][Full Text] [Related]
8. [Drug-induced osteomalacia].
Sato K
Clin Calcium; 2007 Oct; 17(10):1536-42. PubMed ID: 17906405
[TBL] [Abstract][Full Text] [Related]
9. [Bone and Nutrition. The relationship between iron and phosphate metabolism].
Takashi Y; Fukumoto S
Clin Calcium; 2015 Jul; 25(7):1037-42. PubMed ID: 26119317
[TBL] [Abstract][Full Text] [Related]
10. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide.
Suzuki A; Ohoike H; Matsuoka Y; Irimajiri S
Am J Hematol; 1993 May; 43(1):75-6. PubMed ID: 8317471
[No Abstract] [Full Text] [Related]
11. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules.
Sato K; Nohtomi K; Demura H; Takeuchi A; Kobayashi T; Kazama J; Ozawa H
Bone; 1997 Jul; 21(1):57-64. PubMed ID: 9213008
[TBL] [Abstract][Full Text] [Related]
12. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
Amarnani R; Travis S; Javaid MK
Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
[No Abstract] [Full Text] [Related]
13. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
15. [A case of hypophosphatemia induced by intravenous administration of saccharated iron oxide].
Konjiki O; Fukaya S; Kanou H; Imamura T; Iwamoto T; Takasaki M
Nihon Ronen Igakkai Zasshi; 1994 Oct; 31(10):805-10. PubMed ID: 7853746
[TBL] [Abstract][Full Text] [Related]
16. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
17. Managing severe anemia when the patient is a Jehovah's Witness.
Lynn S; McDaniel J
JAAPA; 2013 Apr; 26(4):24, 27-9. PubMed ID: 23610833
[No Abstract] [Full Text] [Related]
18. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study.
Abdel-Razeq H; Abbasi S; Saadi I; Jaber R; Abdelelah H
Drug Des Devel Ther; 2013; 7():939-44. PubMed ID: 24039403
[TBL] [Abstract][Full Text] [Related]
19. Fatal anaphylactic reaction to iron sucrose in pregnancy.
Mishra A; Dave N; Viradiya K
Indian J Pharmacol; 2013; 45(1):93-4. PubMed ID: 23543624
[TBL] [Abstract][Full Text] [Related]
20. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
